Literature DB >> 6838769

Methotrexate inhibits polymorphonuclear leucocyte chemotaxis in psoriasis.

U Walsdorfer, E Christophers, J M Schröder.   

Abstract

Six patients suffering from widespread psoriasis were treated with 20 mg methotrexate (MTX) intramuscularly and the chemotactic activity of peripheral polymorphonuclear leucocytes (PMN) was measured before and after treatment. The modified Boyden chamber method was used and C5a, FMLP, casein and autologous fresh serum served as chemotaxins. Following MTX the chemotactic migration of PMN was inhibited by more than 50% for 2 days and slowly recovered within the following 5 days. The inhibition was present with all of the four chemotaxins used. The results demonstrate that treatment with low dose MTX in patients with psoriasis causes a profound inhibition of PMN function. These findings support the idea that PMN play an important role in the pathogenesis of psoriasis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6838769     DOI: 10.1111/j.1365-2133.1983.tb04598.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Inhibition of neutrophil chemotaxis in methotrexate-treated rheumatoid arthritis patients.

Authors:  J W O'Callaghan; M J Forrest; P M Brooks
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

2.  Methotrexate for steroid-resistant systemic lupus erythematosus.

Authors:  M Hashimoto; S Nonaka; E Furuta; T Wada; Y Suenaga; M Yasuda; M Shingu; M Nobunaga
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

3.  Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa.

Authors:  Kevin T Savage; Elena Gonzalez Brant; Monica Rosales Santillan; Peyton C Morss; Prerna Salian; Kelsey S Flood; Martina L Porter; Alexa B Kimball
Journal:  Int J Womens Dermatol       Date:  2020-02-25

4.  Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.

Authors:  Steven Horwitz; Pier Luigi Zinzani; Martine Bagot; Youn H Kim; Alison J Moskowitz; Pierluigi Porcu; Karen Dwyer; Wei Sun; Fiona M Herr; Julia Scarisbrick
Journal:  Leuk Lymphoma       Date:  2021-07-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.